Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04837677 · ClinicalTrials.gov registry record · Phase 1
A Study of PRT1419 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Prelude Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT04837677 is a Phase 1 study that has completed, run by Prelude Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT04837677, a Phase 1 study, has completed, sponsored by Prelude Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors. The purpose of this study is to define the dosing schedule, maximally tolerated dose and/or estimate the optimal biological dose to be used in subsequent development of PRT1419.
Interventions
- DRUG PRT1419
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-08-11 |
| Est. Completion | 2023-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04837677
The ClinicalTrials.gov registry entry for NCT04837677 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prelude Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRT1419 is the first listed.
NCT04837677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04837677 about?
NCT04837677 is a clinical study titled "A Study of PRT1419 in Patients With Advanced Solid Tumors". This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors. The purpose of this study is to define the dosing schedule, maximally tolerated dose and/or estimate the optimal biological dose to be used in subsequent developmen...
What is the current status of trial NCT04837677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2021-08-11. Estimated completion is 2023-02-06.
What interventions are being tested in trial NCT04837677?
The interventions under investigation include: PRT1419 (DRUG).
Who is sponsoring clinical trial NCT04837677?
This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.